With a 4-0 vote, the FTC has approved final consent orders remedying the anticompetitive effects of Valeant Pharmaceuticals’ proposed acquisitions of Sanofi and Johnson & Johnson’s dermatalogy businesses. For the Sanofi deal, Valeant has sold to Mylan Pharmaceuticals the manufacturing and marketing rights to products treating acne and actinic keratosis. For the Johnson & Johnson deal, Valeant has sold to Spear Pharmaceuticals the rights to an anti-wrinkle pharmaceutical product.
The orders settle charges of Section 7 Clayton Act and Section 5 FTC Act violations.
Source: FTC Press Release
Related content: Consumer Protection Economics at the FTC
Featured News
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI